Rezurock (Belumosudil Tablet) 200mg

Rezurock (belumosudil) 200mg tablets are prescribed for chronic graft-versus-host disease after stem cell transplant. This oral immunosuppressant helps manage immune response in adults and children 12+. Store below 25°C and keep out of reach of children.

Strength

200mg

Pack Size

30s

Storage

Below 25°C

Manufacturer / TM Owner

Kadmon Pharmaceuticals, LLC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Rezurock is used to treat chronic graft-versus-host disease (cGVHD) in adults and pediatric patients aged 12 and older. It belongs to a class of medications called kinase inhibitors, which help reduce inflammation and immune system activity. Patients may take it when cGVHD does not improve with other treatments.

Side Effects

Rezurock works by targeting specific pathways in the immune system to help control symptoms of chronic graft-versus-host disease. Common effects include reduced skin rashes, improved liver function tests, and better overall symptom management. Patients may notice gradual improvement over weeks of consistent use.

Precautions & Warnings

Rezurock should be handled with care, especially by those with liver problems or infections. It may interact with other medications, so inform your healthcare provider about all drugs you take. Keep the medication in its original container and store below 25°C. Do not use if the seal is broken.

Avoid Interactions

Rezurock may interact with strong CYP3A4 inhibitors or inducers, altering its effectiveness. Avoid grapefruit products while taking this medication, as they can affect how the body processes the drug. Discuss all prescription, over-the-counter, and herbal products with your doctor before starting Rezurock.

Frequently Asked Questions

Rezurock is used to treat chronic graft-versus-host disease (cGVHD) in adults and children 12+.

Store Rezurock below 25°C in its original container and keep it away from moisture and light.

Consult your healthcare provider before taking Rezurock with other drugs, as it may interact with certain medications.

Common effects may include nausea, fatigue, or changes in liver function tests.

Rezurock is approved for use in patients aged 12 and older for chronic graft-versus-host disease.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.